Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today it will host a conference call on Wednesday, March 9, 2016 at 8:00 a.m. ET to report fourth quarter and full year 2015 financial results and provide business updates.

To participate in the conference call, please dial 1-877-497-1428 (domestic) or 1-929-387-3949 (international). The live and archived versions of webcast can be accessed under Events in the Investor Center section of the company's website at http://www.epizyme.com.

About Epizyme, Inc.

Epizyme, Inc. is a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of chromatin modifying proteins (CMPs), such as histone methyltransferases or HMTs. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160302005281/en/

Copyright Business Wire 2010